PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

PharmaEngine, Inc.

智擎生技製藥股份有限公司 is involved in the pharmaceutical industry, focusing on the development of anticancer drugs utilizing nanotechnology and checkpoint kinase inhibitors, self-described as a virtual pharmaceutical company.

COM:PHARMAENGINE

智擎生技製藥股份有限公司

Last Close

96.20

22/11 03:19

Market Cap

13.67B

Beta: -

Volume Today

346.46K

Avg: -